Development of new localized drug delivery system based on ceftriaxone-sulbactam composite drug impregnated porous hydroxyapatite: a systematic approach for in vitro and in vivo animal trial.
OBJECTIVE
Present investigation deals with an extensive approach incorporating in vitro and in vivo experimentation to treat chronic osteomyelitis, using hydroxyapatite porous scaffolds.


METHODS
Hydroxyapatite was synthesized in the laboratory by wet chemical method, different porous scaffolds have been fabricated. In vitro studies include variation of porosity with interconnectivity, pore-drug interfacial studies by SEM-EDAX and drug elution studies (by HPLC) both in contact with PBS and SBF at approximately 37 degrees C. In vivo trials were based on experimental osteomyelitis in rabbit model induced in tibia by Staphylococcus aureus. Characterizations included observation of histopathology, radiology and estimation of drug in both bone and serum for 42 days by HPLC method and subsequent bone-biomaterial interface by SEM.


RESULTS
It was established that lower pore percentage with a distribution of mainly micro-pores were found to be superior over the higher pore percentage both in vitro and in vivo. The criteria was matched with the 50N50H samples which had 50-55% porosity with an average pore size approximately 110 microm, having higher interconnectivity (10-100 microm), moderately high adsorption efficiency (approximately 50%) when loaded with CFS (drug combinations consisting of irreversible b-lactamase inhibitor and b-lactam antibiotic). CFS release from HAp implants were faster in PBS than SBF. Further, both the results of in vitro and in vivo drug elution after 42 days showed release higher than minimum inhibitory concentration of CFS against Staphylococcus aureus. In vivo studies also proved the superiority of CFS loaded HAp implants than parenteral group based on eradication of infection and new bone formation.


CONCLUSIONS
HAp based porous scaffold loaded with CFS and designed porosity (in terms of micro- and macro-porosity, interconnectivity) was found to be an ideal delivery system which could locally, sustainably release the composite antibiotic in reliable manner both in terms of in vitro drug elution behaviour in contact with SBF and in vivo animal trial.
Kundu
Biswanath
B
Bioceramics and Coating Division, Central Glass and Ceramic Research Institute, Kolkata, India. biswa_kundu@rediffmail.com
Soundrapandian
Chidambaram
C
Nandi
Samit K
SK
Mukherjee
Prasenjit
P
Dandapat
Nandadulal
N
Roy
Subhasis
S
Datta
Bakul K
BK
Mandal
Tapan K
TK
Basu
Debabrata
D
Bhattacharya
Rupnarayan N
RN
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002443:Ceftriaxone / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004339:Drug Compounding; D016503:Drug Delivery Systems; D017886:Durapatite / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D008855:Microscopy, Electron, Scanning; D010019:Osteomyelitis / Q000188:drug therapy*; D016062:Porosity; D011208:Powders; D011817:Rabbits; D013211:Staphylococcus aureus / Q000187:drug effects; D013407:Sulbactam / Q000008:administration & dosage*; D014961:X-Ray Diffraction
D000900:Anti-Bacterial Agents; D011208:Powders; D002443:Ceftriaxone; D017886:Durapatite; D013407:Sulbactam
Biomaterials. 2004 Aug;25(18):4287-95
15046919
Eur J Pharm Biopharm. 2001 Sep;52(2):151-8
11522480
J Control Release. 2004 Sep 14;99(1):127-37
15342186
Biomaterials. 2001 Jul;22(13):1847-52
11396889
Biomaterials. 2003 May;24(10):1829-31
12593965
Biomaterials. 1998 Apr-May;19(7-9):817-9
9663758
Biomacromolecules. 2009 Jun 8;10(6):1575-83
19348419
AAPS PharmSciTech. 2009;10(4):1158-71
19842042
AAPS PharmSciTech. 2009;10(3):772-9
19499343
Acta Biomater. 2009 Jun;5(5):1686-96
19249262
J Mater Sci Mater Med. 1998 Mar;9(3):159-63
15348905
Acta Orthop Scand. 1994 Jun;65(3):246-52
8042473
Antimicrob Agents Chemother. 1990 Nov;34(11):2070-4
2073099
J R Soc Interface. 2009 Jun 6;6 Suppl 3:S341-8
19106069
Nat Clin Pract Rheumatol. 2007 Dec;3(12):733-8
18037933
Biomaterials. 2002 Aug;23(16):3517-22
12099297
J Mater Sci Mater Med. 2000 Dec;11(12):763-71
15348058
J Control Release. 2006 Jun 28;113(2):102-10
16740332
J Biomed Mater Res. 2001 May;55(2):217-28
11255173
Curr Opin Investig Drugs. 2002 Sep;3(9):1284-90
12498001
Crit Rev Ther Drug Carrier Syst. 2007;24(6):493-545
18298388
Adv Exp Med Biol. 1998;456:71-98
10549364
J Control Release. 2005 Oct 3;107(2):330-42
16085332
Acta Orthop Scand. 1998 Oct;69(5):518-22
9855236
J Biomed Mater Res B Appl Biomater. 2009 Nov;91(2):831-8
19572301
Drugs. 2007;67(2):195-214
17284084
Acta Biomater. 2010 Feb;6(2):641-51
19671456
J Biomed Mater Res B Appl Biomater. 2004 Aug 15;70(2):332-9
15264316
Tissue Eng. 2006 Sep;12(9):2675-83
16995801
Drug Metab Lett. 2007 Jan;1(1):37-40
19356016
J Infect Dis. 1970 Nov;122(5):410-8
5476391
Int J Pharm. 2001 Feb 1;213(1-2):117-25
11165099
Chem Rev. 2008 Nov;108(11):4754-83
19006400
Clin Orthop Relat Res. 1988 Jul;(232):127-38
2838207
Antimicrob Agents Chemother. 1983 May;23(5):692-9
6307133
J Med Chem. 2008 Nov 13;51(21):6955-69
18834106
AAPS PharmSciTech. 2002;3(1):E1
12916954
J Biomed Mater Res B Appl Biomater. 2009 Jul;90(1):210-22
19090489
Int J Nanomedicine. 2008;3(4):403-14
19337409
J Biomed Mater Res. 2002 Jan;59(1):110-7
11745543
J Biomed Mater Res. 1990 Jun;24(6):721-34
2361964
J Biomed Mater Res A. 2005 Dec 1;75(3):588-94
16106435
J Control Release. 2003 Dec 12;93(3):341-54
14644584
Langmuir. 2005 Apr 12;21(8):3232-4
15807558
Biomaterials. 2006 Jun;27(17):3230-7
16488007
Biomaterials. 2002 Jun;23(12):2519-26
12033599
Acta Biomater. 2009 Jul;5(6):2178-88
19303377
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD004439
19588358
J Pharm Sci. 1963 Dec;52:1145-9
14088963